Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor
Lausanne, Switzerland, April 06, 2017 – Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases…